Welcome to International Network for Natural Sciences | INNSpub

Targeting dopamine liposome to brain using polysorbate 80 for parkinson disease

Research Paper | November 1, 2015

| Download 2

I. Sarath Chandran, Pichandy Muthu Prasanna

Key Words:

Int. J. Biosci.7( 5), 107-115, November 2015

DOI: http://dx.doi.org/10.12692/ijb/7.5.107-115


IJB 2015 [Generate Certificate]


The aim of the present study was to prepare and evaluate Dopamine (Dp) liposome using polysorbate 80 (PS80) which enabled the targeted delivery of drug across Blood Brain Barrier (BBB) in the effective treatment of Parkinson disease as L dopa drug conventionally used for Parkinson’s disease produces “wearing off” adverse reactions. Dp loaded liposome were prepared with various concentration of PS80 by Reverse Phase Evaporation technique. The formation of liposome was confirmed by scanning electron microscopy (SEM). The drug and the excipient compatibility was analysed by FTIR, DSC and XRD studies. FTIR indicated that there was no loss in chemical integrity of the drug upon fabrication into liposome. DSC and XRD results demonstrated that the drug was changed from the crystalline form to the amorphous form in the formulation. Among all the formulations, LSP4 showed higher Entrapment efficiency (EE) of 68% and increases the animal locomotion in psychopharmacological study (18.3%). Dp Liposomal formulation LSP4 could be a choice for dopamine delivery directly to brain for Parkinson treatment alternative to conventional use of L dopa thus preventing “wearing of effect.


Copyright © 2015
By Authors and International Network for
Natural Sciences (INNSPUB)
This article is published under the terms of the Creative
Commons Attribution Liscense 4.0

Targeting dopamine liposome to brain using polysorbate 80 for parkinson disease

Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ. 1998. Kreuter J.Significant entry of tubocurarine into the brain of rats by absorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. Journal of Microencapsulation 5, 67-74. http://dx.doi.org/10.3109/02652049809006836

Ann-Kathrine Granérus. 1978. Factors Influencing the Occurrence of “on-off” Symptoms during Long-Term Treatment with L-dopa. Acta Medica Scandinavica 203(1-6), 75-85. http://dx.doi.org/10.1111/j.09546820.1978.tb14835.x

Burkhard schlosshauer, Heikosteuer. 2002. Comparative anatomy, physiology and in vitro models of  blood  brain  barrier  and  blood  retina  barrier  – central  nervous  system  agents.  Current  Medicinal Chemistry-Central Nervous System Agents 2, 175 – 86. http://dx.doi.org/10.2174/1568015023357978

Eldad Melamed, Franz Hefti, Richard J. Wurtman. 1981. Nonaminergic striatal neurons convert   exogenous l-dopa   to dopamine   in parkinsonism. Annals of Neurology 8(6), 558 -563. http://dx.doi.org/10.1002/ana.410080603

Fry, DW, White JC, Goldman ID. 1978. Rapid separation of low molecular weight solutes from liposomes without dilution. Analytical Biochemistry. 90, 809-15. http://dx.doi.org/10.1016/0003-2697(78)90172-0

Quinn  N.  1998.  Classification  of  fluctuations  in Parkinson’s disease. Neurology; 51(Suppl.2), S25–S29. http://dx.doi.org/10.1212/wnl.51.2_suppl_2.s25

Hamdy Abdelkader, Ossama Abdallah Y, Hesham Salem S. 2007. Comparison of the effect of tromethamine and polyvinyl pyrrolidone on the dissolution properties and analgesic effect of nimesulide. AAPS Pharm sci Tech. 8(3), 65-8. http://dx.doi.org/10.1208/pt0803065

Jain Naveen K, Rana AC, Jain Sanjay K. 1998. Brain Drug Delivery System Bearing Dopamine Hydrochloride for Effective Management of Parkinsonism. Drug Development and Industrial Pharmacy 24(7), 671 -675 http://dx.doi.org/10.3109/03639049809082370

Kulkarani SK. 1999. Hand book of experimental pharmacology.3rd ed., New Delhi: Vallabh Prakasham 17-123 p.

Robert Silverstein M, Francis Webster X. 1970. Spectrometric identification of organic compounds. 6th edn., Chap 12 New Jersey: John wiley & sons 136 p.

Maghraby El GMM, Williams AC, Barry BW. 1991. Oestradiol skin delivery from ultradeformable liposomes: refinement of surfactant concentration.in International Journal of Pharmaceutics 196(1), 63-74. http://dx.doi.org/10.1016/s0378-5173(99)00441-x

Philip Seeman. 2006. Targeting the dopamine D2 receptor in schizophrenia. Expert Opinion on Therapeutic Targets 10(4), 515 -531. http://dx.doi.org/10.1517/14728222.10.4.515

Poewe WH, Wenning GK. 1998. The natural history of Parkinson disease. Annals of Neurology 44 (3), S 1– S9. http://dx.doi.org/10.1002/ana.410440703

Schrag A, Quinn N. 2000. Dyskinesias and motor fluctuations in Parkinson’s disease: a community-based study. Brain. 123(11), 2297–2305 http://dx.doi.org/10.1093/brain/123.11.2297

Szoka F, Jr Demetrios Papahadjopoulos. 1978. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proceedings of the National Academy of Sciences, USA, Biochemistry 75, 4194-198. http://dx.doi.org/10.1073/pnas.75.9.4194